Asosiy kontentga oʻtish
Sharh maqola

VEGF/VEGFR-Targeted Therapy and Immunotherapy in Non-small Cell Lung Cancer: Targeting the Tumor Microenvironment

Yueshui ZhaoSouth Sichuan Institute of Translational Medicine, Luzhou, Sichuan 646000, ChinaSipeng GuoLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, ChinaJian Min Deng. Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan 646000, ChinaJing ShenLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, ChinaFukuan DuCell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan 646000, ChinaXu WuSouth Sichuan Institute of Translational Medicine, Luzhou, Sichuan 646000, ChinaYu ChenLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, ChinaMingxing LiSouth Sichuan Institute of Translational Medicine, Luzhou, Sichuan 646000, ChinaMeijuan ChenDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, ChinaXiaobing LiLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, ChinaWanping LiLaboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, ChinaLi Gu. Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, ChinaYuhong Sun. Cell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan 646000, ChinaQinglian WenDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000, ChinaJing Li. Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan 646000, ChinaZhangang XiaoCell Therapy & Cell Drugs of Luzhou Key Laboratory, Luzhou, Sichuan 646000, China
2022en
ABI

Annotatsiya

Non-small cell lung cancer (NSCLC) is the leading cause of death by cancer worldwide. Despite developments in therapeutic approaches for the past few decades, the 5-year survival rate of patients with NSCLC remains low. NSCLC tumor is a complex, heterogeneous microenvironment, comprising blood vessels, cancer cells, immune cells, and stroma cells. Vascular endothelial growth factors (VEGFs) are a major mediator to induce tumor microvasculature and are associated with the progression, recurrence, and metastasis of NSCLC. Current treatment medicines targeting VEGF/VEGF receptor (VEGFR) pathway, including neutralizing antibodies to VEGF or VEGFR and receptor tyrosine kinase inhibitors, have shown good treatment efficacy in patients with NSCLC. VEGF is not only an important angiogenic factor but also an immunomodulator of tumor microenvironment (TME). VEGFs can suppress antigen presentation, stimulate activity of regulatory T (Treg) cells, and tumor-associated macrophages, which in turn promote an immune suppressive microenvironment in NSCLC. The present review focuses on the angiogenic and non-angiogenic functions of VEGF in NSCLC, especially the interaction between VEGF and the cellular components of the TME. Additionally, we discuss recent preclinical and clinical studies to explore VEGF/VEGFR-targeted compounds and immunotherapy as novel approaches targeting the TME for the treatment of NSCLC.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba